logo
Cellectis_Logo
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies

Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today will host a live webcast reviewing updated clinical data on its Phase 1/2a BALLI-01 clinical trial (evaluating UCART22) and on its Phase 1 AMELI-01 clinical trial (evaluating UCART123) that were presented in an oral session on December 12, 2022 at the 64th Annual Meeting of the American Society of Hematology (ASH)

By Cellectis Inc.
Published - Dec 13, 2022, 07:33 AM ET
Last Updated - Apr 08, 2024, 10:14 AM EDT
  • UCART22: anti-tumor activity observed in 60% (n=3) of patients at DL3 using FCA lymphodepletion
  • UCART123:25% (n=2) of patients at DL2 in the FCA arm achieved meaningful response; one patient experienced a durable minimal residual disease (MRD)-negative complete response that continues beyond 12 months
  • BALLI-01 study (evaluating UCART22) now enrolling patients with product candidate manufactured in-house at DL2
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024